Our study demonstrated that the treatment with PAR4-AP inhibited the proliferation of ESCC cells, upregulated p16, and reduced DNMT1 and HDAC2 expression in ESCC cells. The gene discussed is HDAC2; the disease is esophageal squamous cell carcinoma.